“…Efforts to address salivary gland hypofunction and xerostomia have led to the emergence of three interdisciplinary research focus areas: bioengineering of an artificial SG gland, − use of SG and non-SG stem cell therapy, − and delivery of gene therapy. − A substantial body of research has concentrated on the first two aspects, aiming to restore and regenerate the lost gland function. Various research groups have undertaken the challenge of optimizing the SG cell culture, facing inherent difficulties due to the slow proliferation potential and dynamic phenotypic characteristics in vitro. − To address challenges associated with two-dimensional (2D) culture systems, researchers have turned to the development and utilization of innovative biomaterials to mimic and serve as the native extracellular matrix (ECM). ,, A variety of natural, synthetic, and composite biomaterials have been employed to support SG cell growth in three-dimensional (3D) culture for extended periods and for use as transplantation scaffolds. ,, These advancements have also enhanced our understanding of the various SG cell types, including the diversity of stem/progenitor cell populations, which are crucial as treatment targets or for use in stem cell therapy. − Furthermore, efforts have been directed toward comprehending how ECM remodelling and the physicochemical properties of biomaterials influence the SG phenotype and secretory functions, which are paramount for successful clinical applications. ,, Clinical trials, on the other hand, have centered on delivering stem cells and their derivatives from different sources to alleviate xerostomia. In recent times, a handful of human clinical trials have demonstrated the promising potential of autologous mesenchymal stem cells (MSCs) in the treatment of radiation-injured salivary glands. − However, these studies are ongoing and are constrained by several limitations until they are made clinically available.…”